Noble Financial Estimates MariMed's Q1 Earnings

Analysts project losses for the cannabis company in early 2026

Mar. 17, 2026 at 11:22am

Got story updates? Submit your updates here. ›

MariMed Inc., a multi-state cannabis company, has received Q1 2026 earnings per share estimates from analysts at Noble Financial. The firm anticipates MariMed will post a loss of $0.01 per share for the quarter. Noble Financial also provided estimates for the company's Q2, Q3, and Q4 2026 earnings, as well as the full-year 2027, all projecting continued losses.

Why it matters

MariMed's financial performance is closely watched as it operates in the highly competitive and regulated cannabis industry. These earnings estimates from a respected financial firm provide insight into the near-term outlook for the company as it navigates market conditions and expansion efforts.

The details

According to the report, Noble Financial analyst J. Gomes expects MariMed to post a loss of $0.01 per share in Q1 2026. The analyst also forecasts losses of $0.01 per share in Q2 and Q3 2026, and a loss of $0.02 per share in Q4 2026. For the full-year 2027, Noble Financial projects a loss of $0.02 per share for MariMed. Separately, Zacks Research recently upgraded its rating on MariMed stock from 'strong sell' to 'hold'.

  • The earnings estimates were released on March 16, 2026.
  • MariMed is expected to report Q1 2026 earnings in the coming weeks.

The players

Noble Financial

A financial services firm that provides equity research and investment banking services.

J. Gomes

An analyst at Noble Financial who issued the earnings estimates for MariMed.

MariMed Inc.

A multi-state cannabis company focused on cultivation, processing, and retail operations.

Zacks Research

An equity research firm that recently upgraded its rating on MariMed stock.

Got photos? Submit your photos here. ›

What they’re saying

“Noble Financial analyst J. Gomes anticipates that the company will post earnings of ($0.01) per share for the quarter.”

— J. Gomes, Analyst (Noble Financial)

What’s next

MariMed is expected to report its Q1 2026 earnings in the coming weeks, which will provide more insight into the company's financial performance and the accuracy of Noble Financial's projections.

The takeaway

These earnings estimates from Noble Financial highlight the challenges facing MariMed and the broader cannabis industry, as the company is projected to report losses in the near term. Investors will be closely watching MariMed's upcoming Q1 results to gauge the company's ability to navigate the competitive landscape and achieve profitability.